Product Name

Voxtalisib (SAR245409, XL765) Analogue

General description

Voxtalisib Analogue is a dual inhibitor of mTOR/PI3K

Synonym

N-[4-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-methoxy-4-methylbenzamide

Purity

≥98.0%(HPLC)

CAS Number

1349796-36-6

Formula

C³¹H²⁹N⁵O⁶S

Molecular Weight

599.66

Suitability

BioReagent, suitable for cell culture, etc.

l  Physical and Chemical Information

Appearance

solid

Solubility(25℃)

DMSO

≥10mg/mL

Ethanol

Insoluble

Water

Insoluble

l  Biological Information

Biochem/Physiol  Actions

Voxtalisib is a sulfonamide obtained by formal condensation of the sulfonic acid group of 4-[(3-methoxy-4 methylbenzoyl)amino]benzenesulfonic acid with the primary aromatic amino group of N-(3,5-dimethoxyphenyl)quinoxaline 2,3-diamine. A dual PI3K/mTOR inhibitor used in cancer treatment. It has a role as a phosphatidylinositol 3-kinase inhibitor, an antineoplastic agent and a mTOR inhibitor. It is a sulfonamide, a quinoxaline derivative, an aromatic amine, a member of benzamides and an aromatic ether. 

Voxtalisib (SAR245409, XL765) Analogue is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR.

l  Storage

Storage temp.

-20℃

l  Precautions and Disclaimer

This  product is for R&D use only, not for drug, household, or other uses.

l  References

1.    http://www.drugbank.ca

2.    https://ncit.nci.nih.gov

3.    https://www.ncbi.nlm.nih.gov